Status: Recruiting
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
To find the highest tolerable dose of JV-213 (a type of autologous CAR T cell therapy) that can be given to patients who have B-cell lymphoma that is relapsed or refractory.
Participants needed: 33
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: May 18, 2026Locations: 1
Eligibility criteria
For the dose escalation cohort: Eligible patients will include those with r/r B-... [+16]
Active central nervous system (CNS) lymphoma including patients with detectable... [+18]